Open-label, multi-centre, proof of concept phase IIa clinical trial on the efficacy and tolerability of an 8 week oral treatment with once daily 9 mg budesonide in patients with active ulcerative colitis

Trial Profile

Open-label, multi-centre, proof of concept phase IIa clinical trial on the efficacy and tolerability of an 8 week oral treatment with once daily 9 mg budesonide in patients with active ulcerative colitis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Jun 2017

At a glance

  • Drugs Budesonide (Primary)
  • Indications Ulcerative colitis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Dr Falk Pharma
  • Most Recent Events

    • 15 Jun 2017 This trial is completed in Latvia (end date: 20 Feb 2017).
    • 01 Jun 2017 This trial is completed in Hungary (End date: 20 Feb 2017).
    • 30 Mar 2017 This trial is completed in Lithuania (End date: 20 Feb 2017), according to Eudra record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top